Suppression of 11beta-hydroxysteroid dehydrogenase type 1 with RNA interference substantially attenuates 3T3-L1 adipogenesis - PubMed (original) (raw)
Suppression of 11beta-hydroxysteroid dehydrogenase type 1 with RNA interference substantially attenuates 3T3-L1 adipogenesis
Yong Liu et al. Physiol Genomics. 2008.
Abstract
11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1), which regulates the local level of glucocorticoids, has been suggested to be involved in the development of obesity. A definitive functional role for 11beta-HSD1 in adipogenesis, however, remains to be established. We developed 3T3-L1 cell lines stably transfected with a small hairpin RNA (shRNA) targeting 11beta-HSD1. A shRNA containing two nucleotide substitutions was used as a control. Silencing of 11beta-HSD1 substantially attenuated the accumulation of lipid droplets and the expression of adipogenesis marker genes, which was induced by a mixture containing either corticosterone or dexamethasone. Silencing of 11beta-HSD1 increased the concentration of 11-dehydrocorticosterone in the culture supernatant but did not significantly affect the levels of corticosterone or dexamethasone. Translocation of glucocorticoid receptors to the nucleus in response to glucocorticoids was significantly attenuated by silencing 11beta-HSD1. The number of cells entering the S phase of the cell cycle following the induction of adipogenesis was significantly reduced by silencing 11beta-HSD1. 11beta-HSD1 shRNA delivered by lentiviral vectors after the induction of differentiation, however, did not affect the progression of adipogenesis. These results indicate that 11beta-HSD1 plays a significant functional role in the initiation of 3T3-L1 adipogenesis and provide new mechanistic insights into the role of 11beta-HSD1 in the development of obesity and related diseases.
Similar articles
- Role of 11-beta-hydroxysteroid dehydrogenase type 1 in differentiation of 3T3-L1 cells and in rats with diet-induced obesity.
Liu Y, Sun WL, Sun Y, Hu G, Ding GX. Liu Y, et al. Acta Pharmacol Sin. 2006 May;27(5):588-96. doi: 10.1111/j.1745-7254.2006.00316.x. Acta Pharmacol Sin. 2006. PMID: 16626514 - Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344).
Park JS, Rhee SD, Kang NS, Jung WH, Kim HY, Kim JH, Kang SK, Cheon HG, Ahn JH, Kim KY. Park JS, et al. Biochem Pharmacol. 2011 Apr 15;81(8):1028-35. doi: 10.1016/j.bcp.2011.01.020. Epub 2011 Feb 18. Biochem Pharmacol. 2011. PMID: 21315688 - Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
Nakano S, Inada Y, Masuzaki H, Tanaka T, Yasue S, Ishii T, Arai N, Ebihara K, Hosoda K, Maruyama K, Yamazaki Y, Shibata N, Nakao K. Nakano S, et al. Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1213-22. doi: 10.1152/ajpendo.00340.2006. Epub 2006 Dec 26. Am J Physiol Endocrinol Metab. 2007. PMID: 17190905 - Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH, Walker BR. Stimson RH, et al. Minerva Endocrinol. 2007 Sep;32(3):141-59. Minerva Endocrinol. 2007. PMID: 17912154 Review. - Local amplification of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response.
Chapman KE, Coutinho A, Gray M, Gilmour JS, Savill JS, Seckl JR. Chapman KE, et al. Ann N Y Acad Sci. 2006 Nov;1088:265-73. doi: 10.1196/annals.1366.030. Ann N Y Acad Sci. 2006. PMID: 17192572 Review.
Cited by
- Chronic glucocorticoid exposure-induced epididymal adiposity is associated with mitochondrial dysfunction in white adipose tissue of male C57BL/6J mice.
Yu J, Yu B, He J, Zheng P, Mao X, Han G, Chen D. Yu J, et al. PLoS One. 2014 Nov 12;9(11):e112628. doi: 10.1371/journal.pone.0112628. eCollection 2014. PLoS One. 2014. PMID: 25389775 Free PMC article. - Renal Tumor Necrosis Factor α Contributes to Hypertension in Dahl Salt-Sensitive Rats.
Huang B, Cheng Y, Usa K, Liu Y, Baker MA, Mattson DL, He Y, Wang N, Liang M. Huang B, et al. Sci Rep. 2016 Feb 26;6:21960. doi: 10.1038/srep21960. Sci Rep. 2016. PMID: 26916681 Free PMC article. - Novel role of fumarate metabolism in dahl-salt sensitive hypertension.
Tian Z, Liu Y, Usa K, Mladinov D, Fang Y, Ding X, Greene AS, Cowley AW Jr, Liang M. Tian Z, et al. Hypertension. 2009 Aug;54(2):255-60. doi: 10.1161/HYPERTENSIONAHA.109.129528. Epub 2009 Jun 22. Hypertension. 2009. PMID: 19546378 Free PMC article. - Renal medullary 11 beta-hydroxysteroid dehydrogenase type 1 in Dahl salt-sensitive hypertension.
Liu Y, Singh RJ, Usa K, Netzel BC, Liang M. Liu Y, et al. Physiol Genomics. 2008 Dec 12;36(1):52-8. doi: 10.1152/physiolgenomics.90283.2008. Epub 2008 Sep 30. Physiol Genomics. 2008. PMID: 18826995 Free PMC article. - Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.
Hoffmann BR, El-Mansy MF, Sem DS, Greene AS. Hoffmann BR, et al. J Med Chem. 2012 Oct 11;55(19):8260-71. doi: 10.1021/jm301204r. Epub 2012 Sep 28. J Med Chem. 2012. PMID: 22970990 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources